A Phase 2 Study of Methimazole in Patients With Progressive Glioblastoma
Status:
Not yet recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug
called Methimazole. The investigational drug, Methimazole is not FDA approved for brain
tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be
given to several study participants with glioblastoma. The first several study participants
will receive the lowest dose. If the drug does not cause serious side effects, it will be
given to other study participants at a higher dose. The doses will continue to increase for
every group of study participants until the side effects occur that require the dose to be
lowered. The procedures in this study are research blood draws, physical exams, collection of
medical history, MRI scans, and study drug administration.